ECRD 2014 TREAT-NMD as a funded network and new funding opportunities Kate Bushby Newcastle University @bushbykate

First Page		Document Content
Date: 2014-05-20 04:36:22 Genetic genealogy TREAT-NMD Limb-girdle muscular dystrophy Duchenne muscular dystrophy Centronuclear myopathy Spinal muscular atrophy Neuromuscular disease Congenital muscular dystrophy Myopathy Health Muscular dystrophy Medicine		ECRD 2014 TREAT-NMD as a funded network and new funding opportunities Kate Bushby Newcastle University @bushbykate Add to Reading List Source URL: www.rare-diseases.eu Download Document from Source Website File Size: 2,24 MB Share Document on Facebook

	Mutations in BICD2 Cause Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraplegia DocID: 1uWce - View Document
	Fostering Health and Growth for Spinal Muscular Atrophy SMA CARE SERIES Nutrition Basics DocID: 1trbw - View Document
	TRAINING IMPROVES OXIDATIVE CAPACITY, BUT NOT FUNCTION, IN SPINAL MUSCULAR ATROPHY TYPE III DocID: 1tqwe - View Document
	Resistance Strength Training Exercise in Children with Spinal Muscular Atrophy Aga Lewelt, MD, MS1; Kristin J. Krosschell, PT, DPT, MA, PCS2; Gregory J. Stoddard, MS3; Cindy Weng, MS3; Mei Xue, MS4; Robin L. Marcus, PT, DocID: 1tqop - View Document
	Dear Primary Care Provider, Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disease characterized by weakness of the skeletal and respiratory muscles. SMA is a rare disorder occurring approximately 1 in 10,000 b DocID: 1tkD5 - View Document